RESUMEN
Significance: Achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a significant predictor of increased likelihood of survival in breast cancer patients. Early prediction of pCR is of high clinical value as it could allow personalized adjustment of treatment regimens in non-responding patients for improved outcomes. Aim: We aim to assess the association between hemoglobin-based functional imaging biomarkers derived from diffuse optical tomography (DOT) and the pathological outcome represented by pCR at different timepoints along the course of NACT. Approach: Twenty-two breast cancer patients undergoing NACT were enrolled in a multimodal DOT and X-ray digital breast tomosynthesis (DBT) imaging study in which their breasts were imaged at different compression levels. Logistic regressions were used to study the associations between DOT-derived imaging markers evaluated after the first and second cycles of chemotherapy, respectively, with pCR status determined after the conclusion of NACT at the time of surgery. Receiver operating characteristic curve analysis was also used to explore the predictive performance of selected DOT-derived markers. Results: Normalized tumor HbT under half compression was significantly lower in the pCR group compared to the non-pCR group after two chemotherapy cycles (p=0.042). In addition, the change in normalized tumor StO2 upon reducing compression from full to half mammographic force was identified as another potential indicator of pCR at an earlier time point, i.e., after the first chemo cycle (p=0.038). Exploratory predictive assessments showed that AUCs using DOT-derived functional imaging markers as predictors reach as high as 0.75 and 0.71, respectively, after the first and second chemo cycle, compared to AUCs of 0.50 and 0.53 using changes in tumor size measured on DBT and MRI. Conclusions: These findings suggest that breast DOT could be used to assist response assessment in women undergoing NACT, a critical but unmet clinical need, and potentially enable personalized adjustments of treatment regimens.
Asunto(s)
Neoplasias de la Mama , Terapia Neoadyuvante , Tomografía Óptica , Humanos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/patología , Femenino , Terapia Neoadyuvante/métodos , Persona de Mediana Edad , Tomografía Óptica/métodos , Adulto , Hemodinámica , Resultado del Tratamiento , Mamografía/métodos , Mama/diagnóstico por imagen , Mama/patología , Hemoglobinas/análisis , Anciano , Biomarcadores de Tumor/análisis , Curva ROCRESUMEN
Breast cancer screening is necessary to reduce mortality due to undetected breast cancer. Current methods have limitations, and as a result many women forego regular screening. Magnetic resonance imaging (MRI) can overcome most of these limitations, but access to conventional MRI is not widely available for routine annual screening. Here, we used an MRI scanner operating at ultra-low field (ULF) to image the left breasts of 11 women (mean age, 35 years ±13 years) in the prone position. Three breast radiologists reviewed the imaging and were able to discern the breast outline and distinguish fibroglandular tissue (FGT) from intramammary adipose tissue. Additionally, the expert readers agreed on their assessment of the breast tissue pattern including fatty, scattered FGT, heterogeneous FGT, and extreme FGT. This preliminary work demonstrates that ULF breast MRI is feasible and may be a potential option for comfortable, widely deployable, and low-cost breast cancer diagnosis and screening.
RESUMEN
Near-infrared diffuse optical tomography (DOT) has the potential to improve the accuracy of breast cancer diagnosis and aid in monitoring the response of breast tumors to chemotherapy by providing hemoglobin-based functional imaging. The use of structural lesion priors derived from clinical breast imaging methods, such as mammography, can improve recovery of tumor optical contrast; however, accurate lesion prior placement is essential to take full advantage of prior-guided DOT image reconstruction. Simultaneous optical and anatomical imaging may not always be possible or desired, which can make the accurate registration of the lesion prior challenging. In this paper, we present a three-step lesion prior scanning approach to facilitate improved accuracy in lesion localization based on the optical contrast quantified by the total hemoglobin concentration (HbT) for non-simultaneous multimodal DOT and digital breast tomosynthesis (DBT) imaging. In three challenging breast cancer patient cases, where no clear optical contrast was present initially, we have demonstrated consistent improvement in the recovered HbT lesion contrast by utilizing this method.
RESUMEN
Diffuse optical tomography (DOT) is emerging as a noninvasive functional imaging method for breast cancer diagnosis and neoadjuvant chemotherapy monitoring. In particular, the multimodal approach of combining DOT with x-ray digital breast tomosynthesis (DBT) is especially synergistic as DBT prior information can be used to enhance the DOT reconstruction. DOT, in turn, provides a functional information overlay onto the mammographic images, increasing sensitivity and specificity to cancer pathology. We describe a dynamic DOT apparatus designed for tight integration with commercial DBT scanners and providing a fast (up to 1 Hz) image acquisition rate to enable tracking hemodynamic changes induced by the mammographic breast compression. The system integrates 96 continuous-wave and 24 frequency-domain source locations as well as 32 continuous wave and 20 frequency-domain detection locations into low-profile plastic plates that can easily mate to the DBT compression paddle and x-ray detector cover, respectively. We demonstrate system performance using static and dynamic tissue-like phantoms as well as in vivo images acquired from the pool of patients recalled for breast biopsies at the Massachusetts General Hospital Breast Imaging Division.
Asunto(s)
Neoplasias de la Mama/diagnóstico por imagen , Mamografía/métodos , Imagen Multimodal/métodos , Mama/diagnóstico por imagen , Femenino , Humanos , Procesamiento de Imagen Asistido por Computador , Persona de Mediana Edad , Distribución Normal , Óptica y Fotónica , Fantasmas de Imagen , Ondas de Radio , Tomografía ÓpticaRESUMEN
UNLABELLED: Assessment of a pediatric breast lesion always starts with clinical evaluation. When imaging of a pediatric breast is indicated, ultrasound is the mainstay. The vast majority of pediatric breast complaints are of benign etiology, therefore the diagnostic/management approach emphasizes "first do no harm". Correlation with age and clinical history helps to direct diagnosis. It is essential to be familiar with the imaging appearance of the normal developing breast at various Tanner stages, in order to diagnose physiologic breast findings and to minimize unnecessary biopsies in young breasts vulnerable to injury. Normal anatomic structures, developmental conditions, benign neoplastic and non-neoplastic lesions are common causes of breast complaints in children. Uncommon benign masses and rarely, secondary more than primary malignancies may present in a pediatric breast. Chest wall masses such as Ewing's sarcoma or rhabdomyosarcoma occur in children and may involve the breast via contiguous growth or locoregional metastasis. In addition, special attention should be given to any breast lesion in a child with risk factors predisposing to breast cancer, such as known extramammary malignancy, genetic mutations, prior mantle irradiation, or strong family history of breast cancer, which usually requires biopsy to exclude the possibility of malignancy. CONCLUSION: The developing breast is vulnerable to injury, and because breast malignancy is uncommon in children, diagnostic and management approach emphasizes "first do no harm". Understanding normal breast development and the spectrum of common and uncommon pediatric breast lesions are key to the correct diagnosis.
Asunto(s)
Enfermedades de la Mama/diagnóstico por imagen , Neoplasias de la Mama/diagnóstico por imagen , Adolescente , Desarrollo del Adolescente , Adulto , Mama/ultraestructura , Niño , Desarrollo Infantil , Preescolar , Femenino , Humanos , Masculino , Mamografía , Pubertad , Factores de Riesgo , Tomografía Computarizada por Rayos X , Ultrasonografía Mamaria , Adulto JovenRESUMEN
Methods of axillary evaluation in invasive breast cancer continue to evolve. The recent American College of Surgeons Oncology Group Z0011 Trial is a prospective, randomized, multicenter trial that compared the survival and locoregional recurrence rates after complete axillary lymph node dissection (ALND) versus sentinel node biopsy (SNB) alone in women with a positive sentinel node in an effort to avoid the complications associated with ALND. As the results of this trial are implemented clinically, affecting surgical management of axillary metastatic disease, radiologists may need to redefine their role in the preoperative assessment of the axilla. Before the Z0011 trial, breast imagers worked to identify axillary metastases preoperatively, allowing appropriate patients to proceed directly to ALND and avoiding the need for SNB. However, the Z0011 trial concluded that ALND may not be necessary in women with metastatic axillary disease who meet the trial criteria. In the Z0011 trial, after 6 years of median follow-up there was no difference in either locoregional recurrence or survival among the women who underwent SNB alone compared with those who underwent ALND, suggesting that ALND is unnecessary in a subset of women with a positive node at SNB. These results raise questions about how aggressively radiologists should pursue percutaneous sampling of axillary nodes, as some practitioners conclude that, in an otherwise eligible woman, positive results from imaging-guided percutaneous biopsy preclude a Z0011 trial-directed pathway. Debate about the best way to implement the results of the Z0011 trial into daily clinical practice exists. It is important for breast imagers to work closely with breast surgeons to provide the most appropriate treatment course for each patient.
Asunto(s)
Axila/patología , Neoplasias de la Mama/patología , Biopsia Guiada por Imagen , Biopsia del Ganglio Linfático Centinela , Femenino , Humanos , Metástasis Linfática , Invasividad NeoplásicaAsunto(s)
Neoplasias de la Mama/patología , Carcinoma Ductal de Mama/patología , Bocio Nodular , Síndrome de Hamartoma Múltiple/patología , Glándula Tiroides/patología , Adulto , Femenino , Predisposición Genética a la Enfermedad , Humanos , Tumor Filoide/patología , Recurrencia , Nódulo Tiroideo , Lengua/patologíaRESUMEN
Thirty patients with prostate or bladder cancer underwent CT and MRI for nodal staging. CT detected 189 nodes, and MRI detected 271 nodes. This difference was statistically significant in the external iliac (CT/MRI=73/87 nodes), obturator (CT/MRI=48/75 nodes), and internal iliac (CT/MRI=24/46 nodes) nodal chains. Based on size, the number of nodes detected by CT and MRI were as follows: 1-5 mm, CT/MRI=91/166; 6-10 mm, CT/MRI=91/98; >10 mm, CT/MRI=7/7 nodes. MRI detected significantly more lymph nodes in the size range of 1-5 mm.
Asunto(s)
Ganglios Linfáticos/diagnóstico por imagen , Ganglios Linfáticos/patología , Metástasis Linfática/diagnóstico , Imagen por Resonancia Magnética/métodos , Neoplasias de la Próstata/patología , Tomografía Computarizada Espiral/métodos , Neoplasias de la Vejiga Urinaria/patología , Anciano , Anciano de 80 o más Años , Medios de Contraste , Femenino , Gadolinio DTPA , Humanos , Aumento de la Imagen/métodos , Procesamiento de Imagen Asistido por Computador/métodos , Masculino , Persona de Mediana Edad , Variaciones Dependientes del Observador , Reproducibilidad de los Resultados , Estudios RetrospectivosAsunto(s)
Neoplasias de Células Germinales y Embrionarias/patología , Neoplasias Testiculares/patología , Testículo/patología , Adulto , Antineoplásicos/uso terapéutico , Biomarcadores de Tumor/análisis , Cisplatino/uso terapéutico , Diagnóstico Diferencial , Humanos , Escisión del Ganglio Linfático , Masculino , Estadificación de Neoplasias , Neoplasias de Células Germinales y Embrionarias/diagnóstico por imagen , Neoplasias de Células Germinales y Embrionarias/cirugía , Neoplasias Testiculares/diagnóstico por imagen , Neoplasias Testiculares/cirugía , Testículo/diagnóstico por imagen , UltrasonografíaAsunto(s)
Diagnóstico por Imagen/métodos , Diagnóstico por Imagen/tendencias , Neoplasias de la Vejiga Urinaria/patología , Cistoscopía , Humanos , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Metástasis de la Neoplasia/patología , Estadificación de Neoplasias , Tomografía de Emisión de Positrones , Pronóstico , Ultrasonografía , Neoplasias de la Vejiga Urinaria/diagnóstico por imagenRESUMEN
Accurate nodal staging is important in the management of any primary malignancy. The presence of nodal metastases has both therapeutic and prognostic implications. Lymphotropic nanoparticles are a new class of MRI contrast agents, which are promising in detecting minimal metastatic nodal disease particularly in normal sized lymph nodes. This paper discusses the technique and interpretation of lymphotropic nanoparticle enhanced MRI (LNMRI) and reviews the various trials evaluating nodal staging with ferumoxtran-10 enhanced MRI.
Asunto(s)
Aumento de la Imagen/métodos , Ganglios Linfáticos/patología , Imagen por Resonancia Magnética/métodos , Nanoestructuras , Medios de Contraste/administración & dosificación , Medios de Contraste/efectos adversos , Dextranos , Óxido Ferrosoférrico , Humanos , Hierro/efectos adversos , Metástasis Linfática , Nanopartículas de Magnetita , Ilustración Médica , Nanoestructuras/efectos adversos , Estadificación de Neoplasias , Óxidos/efectos adversos , Reproducibilidad de los Resultados , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: Ferumoxtran-10 is a lymphotropic MR contrast agent that is currently under investigation. It has been shown to be effective in staging lymph nodes of patients with various primary malignancies. The current technique with ferumoxtran-10 involves imaging before and 24 hr after contrast administration. The purpose of this study was to evaluate the accuracy of ferumoxtran-10-enhanced images alone in characterizing lymph nodes for oncologic staging 24 hr after contrast enhancement. MATERIALS AND METHODS: Seventy-seven patients (58 men, 19 women) with proven primary cancer (bladder [n = 20], breast [n = 10], endometrial [n = 1], renal [n = 3], penile [n = 4], prostate [n = 31], rectal [n = 1], testicular [n = 5], and ureteral [n = 2]) who were scheduled for surgical lymph node dissection were enrolled in the study. In these patients, 169 lymph nodes (mean size, 11.2 mm) were evaluated on T2*-weighted gradient-refocused echo MRI at l.5 T both before and 24-36 hr after the IV administration of ferumoxtran-10 (2.6 mg Fe/kg). Two blinded reviewers with differing levels of interpreting experience separately performed qualitative image evaluation. A 6-point scale was used to characterize lymph nodes on contrast-enhanced images alone and on combined unenhanced and contrast-enhanced images. Receiver operating characteristic (ROC) analysis was performed separately for both reviewers. RESULTS: Of the 169 lymph nodes evaluated, 55 were benign and 114 malignant by histopathologic analysis. The results of the ROC analysis comparing contrast-enhanced images ([A(z) = area under ROC curve] reviewer 1, A(z) = 0.92; reviewer 2, A(z) = 0.94) alone with combined unenhanced and contrast-enhanced images (reviewer 1, A(z) = 0.94; reviewer 2, A(z) = 0.93) showed a statistically significant difference (p = 0.01) for reviewer 1 but no difference for reviewer 2 (p = 0.88). Reviewer 2 was more experienced in interpreting ferumoxtran-10-enhanced images than reviewer 1. CONCLUSION: On ferumoxtran-10-enhanced MR lymphangiography, contrast-enhanced images alone may suffice for lymph node characterization. However, a certain level of interpretation experience may be required before contrast-enhanced images can be used alone.
Asunto(s)
Medios de Contraste , Hierro , Ganglios Linfáticos/patología , Metástasis Linfática/diagnóstico , Imagen por Resonancia Magnética/métodos , Óxidos , Adulto , Anciano , Anciano de 80 o más Años , Dextranos , Femenino , Óxido Ferrosoférrico , Humanos , Nanopartículas de Magnetita , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Curva ROC , Sensibilidad y EspecificidadRESUMEN
Detection of local or regional metastases to lymph nodes is clinically important in virtually any type of primary tumor. Current imaging techniques rely heavily on the size criterion for characterization of nodal disease. However, size can be an ineffective parameter for diagnosis of tumor spread to lymph nodes. Magnetic resonance (MR) imaging performed before and after administration of ferumoxtran-10 is a promising technique for characterization of lymph nodes in patients with various primary tumors. Normal homogeneous uptake of ferumoxtran-10 in nonmetastatic nodes shortens the T2 and T2*, turning these nodes dark, whereas malignant nodes lack uptake and remain hyperintense. To optimize acquisition strategies, the following factors should be considered: the timing of contrast material-enhanced imaging, the section thickness, the imaging plane, and the imaging parameters for T2*-weighted sequences. In addition, MR imaging with ferumoxtran-10 allows presurgical mapping of lymph nodes and quantitative estimation of T2*.